ROCHESTER, N.Y., Sept. 22, 2021 /PRNewswire/ -- GreenLight
Biosciences, Inc., a biotechnology company focused on RNA
research, design, and manufacturing for human, animal, and plant
health, announced the opening of its manufacturing plant in
Rochester, New York, Bloomberg
reports.
The 17,000-square-foot facility will manufacture enzymes and RNA
for a variety of agricultural applications, including the
protection of honeybees.
While the fast rollout of mRNA vaccines helped change the course
of the pandemic, RNA also has numerous potential applications in
plant and animal health.
To date, however, the cost and scale of RNA production has
constrained the development of its use in agriculture.
"GreenLight has developed a new way to produce commercial
quantities of RNA at low cost for multiple applications," says
chief operating officer Carole Cobb.
"GreenLight's research know-how and production process allows us to
address some of the challenges that formerly hindered RNA's
application in agriculture."
Sustainable alternatives to chemical-based pesticides are needed
to protect biodiversity, including beneficial insects and
pollinators. GreenLight's agricultural solutions are designed to
protect biodiversity through their specificity in targeting pests
like the Varroa destructor mite, which contributes to the collapse
of beehives, and the Colorado
potato beetle, which destroys potato plants.
"Rochester has a proud history
of being on the cutting edge of technological innovation, and
GreenLight Biosciences continues that legacy," said Rep.
Joe Morelle (D–N.Y.). "This new
production facility will be critical to advancing RNA applications
and strengthening our agricultural economy. I am excited to welcome
GreenLight Biosciences into Eastman Business Park and
look forward to their continued growth and success."
Located within the 1,200-acre Eastman Business Park, the
Rochester manufacturing facility
has an installed capacity at 500 kg per year, with ready expansion
to 1,000 kg. The site and utility infrastructure supports a further
expansion of RNA production up to 100 metric tons per year.
About GreenLight Biosciences, Inc.
Founded in
2008, GreenLight has raised approximately $235 million to date and is rapidly expanding to
new market opportunities in human health, animal health, and plant
health. GreenLight harnesses the power of biology to develop
RNA-based solutions for some of humanity's greatest challenges in
human health through mRNA vaccines and therapeutics and in food
production through RNA crop-protection products. The
company's breakthrough cell-free RNA manufacturing platform,
which is protected by numerous patents, allows for cost-effective
and scalable production of RNA. For more information, visit
https://www.greenlightbiosciences.com/
In August 2021, GreenLight
Biosciences announced plans to become publicly listed through a
business combination with Environmental Impact Acquisition Corp.
(Nasdaq:ENVI).
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, with respect to the proposed transaction between GreenLight
Biosciences, Inc. ("GreenLight") and Environmental Impact
Acquisition Corp. ("ENVI"). These forward-looking statements
generally are identified by the words "believe," "project,"
"expect," "anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result" and similar expressions. Many
factors could cause actual future events to differ materially from
the forward-looking statements in this press release, including but
not limited to the risk that the transaction may not be completed
in a timely manner or at all, which may adversely affect the price
of ENVI's securities and the effect of the announcement or pendency
of the transaction on GreenLight's business relationships,
operating results, and business generally. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and ENVI and GreenLight assume no obligation and do not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Thomas Crampton
SVP & Head of Corporate Affairs
GreenLight Biosciences
tcrampton@greenlightbio.com
+44 7826 995794
+1-914-202-2762
View original content to download
multimedia:https://www.prnewswire.com/news-releases/greenlight-biosciences-opens-rna-production-facility-for-the-next-generation-of-agricultural-products-301383973.html
SOURCE GreenLight Biosciences
